House Oversight chair presses FDA on China amid growing tensions

House Over­sight Com­mit­tee Chair James Com­er (R-KY) is press­ing the FDA to share more in­for­ma­tion on its pres­ence in Chi­na amid grow­ing con­cerns on Capi­tol Hill about Chi­nese in­volve­ment in biotech and oth­er in­dus­tries.

The FDA’s mon­i­tor­ing ac­tiv­i­ties in Chi­na haven’t been com­pli­ant since be­fore the Covid-19 pan­dem­ic, Com­er wrote in a 14-page let­ter sent to FDA Com­mis­sion­er Robert Califf. The let­ter un­der­scores that Chi­na is a dom­i­nant man­u­fac­tur­er of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents and that qual­i­ty con­trol is­sues at Chi­nese fa­cil­i­ties have led to short­ages of drugs and de­vices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.